Check-Cap Ltd. (NASDAQ:CHEK) Short Interest Down 14.6% in September

Check-Cap Ltd. (NASDAQ:CHEK) was the recipient of a large decrease in short interest in September. As of September 15th, there was short interest totalling 56,000 shares, a decrease of 14.6% from the August 31st total of 65,600 shares. Based on an average daily trading volume, of 10,900 shares, the days-to-cover ratio is presently 5.1 days. Approximately 1.3% of the company’s shares are short sold.

Check-Cap Price Performance

Shares of CHEK stock traded down $0.18 during trading hours on Friday, reaching $1.17. The company had a trading volume of 59,468 shares, compared to its average volume of 96,044. The company has a 50 day moving average of $1.85 and a 200 day moving average of $2.09. The firm has a market cap of $6.87 million, a price-to-earnings ratio of -0.39 and a beta of 0.39. Check-Cap has a 1-year low of $1.13 and a 1-year high of $4.59.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on Check-Cap in a report on Sunday, September 22nd. They set a “sell” rating on the stock.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.